Cargando…

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease

OBJECTIVE: To determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from disease onset. METHODS: Prospectively collected, longitudinal (untreated, disease onset to year 5), observational data from Parkinson's Progression Markers Initiative an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weintraub, Daniel, Caspell‐Garcia, Chelsea, Simuni, Tanya, Cho, Hyunkeun R., Coffey, Christopher S., Aarsland, Dag, Alcalay, Roy N., Barrett, Matthew J., Chahine, Lana M., Eberling, Jamie, Espay, Alberto J., Hamilton, Jamie, Hawkins, Keith A., Leverenz, James, Litvan, Irene, Richard, Irene, Rosenthal, Liana S., Siderowf, Andrew, York, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187707/ https://www.ncbi.nlm.nih.gov/pubmed/32285645 http://dx.doi.org/10.1002/acn3.51022

Ejemplares similares

Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
por: Chahine, Lana M., et al.
Publicado: (2018)

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
por: Caspell-Garcia, Chelsea, et al.
Publicado: (2017)

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)

Ballantyne's Quinquennium of Medicine and Surgery
Publicado: (1911)

Quinquennium of Medicine and Surgery, 1906 to 1910
Publicado: (1911)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
por: Weintraub, Daniel, et al.
Publicado: (2023)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
por: Chahine, Lana M., et al.
Publicado: (2020)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression
por: Pereira, Joana B., et al.
Publicado: (2019)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Data on the annual aggregated income taxes of the Italian municipalities over the quinquennium 2007–2011
por: Ausloos, Marcel, et al.
Publicado: (2018)

Psychiatric and neuropsychiatric syndromes and COVID-19
por: Velayudhan, Latha, et al.
Publicado: (2020)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

The importance of co-pathologies on neuropsychiatric symptoms in dementia
por: Gibson, Lucy L., et al.
Publicado: (2022)

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older
por: Brumm, Michael C., et al.
Publicado: (2023)

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016)

Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia
por: Giil, Lasse M., et al.
Publicado: (2021)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
por: Mueller, Christoph, et al.
Publicado: (2020)

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
por: Simuni, Tanya, et al.
Publicado: (2020)

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
por: Bloniecki, Victor, et al.
Publicado: (2020)

Imaging Studies of Aging, Neurodegenerative Disease, and Alcoholism
por: Eberling, Jamie L., et al.
Publicado: (1995)

Diagnosis and management of Parkinson's disease dementia
por: Poewe, W, et al.
Publicado: (2008)

Epilepsy and TSC-Associated Neuropsychiatric Disorders
por: Capal, Jamie K.
Publicado: (2020)

Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
por: Chahine, Lana M., et al.
Publicado: (2023)

Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia
por: Solvang, Stein-Erik Hafstad, et al.
Publicado: (2019)

Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine
por: Dave, Sonali, et al.
Publicado: (2019)

Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
por: Picillo, Marina, et al.
Publicado: (2022)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies
por: Jaramillo-Jimenez, Alberto, et al.
Publicado: (2021)

Neuroendocrine Abnormalities Following Traumatic Brain Injury: An Important Contributor to Neuropsychiatric Sequelae
por: Molaie, Amir M., et al.
Publicado: (2018)

Environmental Exposures and Parkinson’s Disease
por: Nandipati, Sirisha, et al.
Publicado: (2016)

PET 6-[(18)F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates
por: Eberling, Jamie L., et al.
Publicado: (2008)

Impact of the Covid‐19 pandemic on neuropsychiatric symptoms and antipsychotic prescribing for people with dementia in nursing home settings
por: McDermid, Joanne, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ese5naeo5lkb89a9lqt47gfh63